Weight Loss Peptides is a recurring topic in our peptide coverage. This hub collects every article tagged Weight Loss Peptides, newest first, each evidence-graded and tied to real, verifiable sources.
The honest, evidence-first ranking of peptides for weight loss — the GLP-1-based incretin agonists that work in human RCTs, and the 'fat-burning' GH-fragment peptides that failed in human trials.
An evidence-graded review of the peptide drugs studied for metabolic syndrome — from the Grade A incretin drugs that reverse the whole cluster to the preclinical-only compounds sold online with no completed human trial.
Beyond Ozempic and Wegovy: a clinical-evidence ranking of the next-generation metabolic peptides — the dual and triple incretin agonists and amylin analogues — for weight loss in 2026.
A clinical monograph on tirzepatide — the dual GIP/GLP-1 co-agonist sold as Mounjaro and Zepbound. Grade-A RCT evidence for diabetes, obesity and sleep apnea, with a boxed warning and a tightening 2026 compounding landscape.
A clinical monograph on survodutide (BI 456906) — the investigational once-weekly GLP-1/glucagon dual agonist. Grade A randomized evidence in obesity and MASH, but not approved anywhere as of mid-2026.
A clinical monograph on semaglutide — the long-acting GLP-1 receptor agonist behind Ozempic, Wegovy and Rybelsus. Grade-A human RCT evidence across diabetes, obesity, cardiovascular, kidney and liver disease.
A clinical monograph on retatrutide (LY3437943) — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist with the largest pharmacologic weight loss reported to date, graded A on human Phase 3 RCTs, but FDA-unapproved and WADA-prohibited as of mid-2026.
A clinical monograph on pramlintide — the synthetic amylin analog and only non-insulin mealtime adjunct FDA-approved for type 1 and type 2 diabetes, with Grade-A human RCT evidence and a boxed warning for severe hypoglycemia.
A clinical monograph on mazdutide (IBI362 / LY3305677) — the first GLP-1/glucagon dual receptor agonist, backed by completed Phase 3 RCTs for obesity and type 2 diabetes, approved in China but investigational in the US.
A clinical monograph on CagriSema — Novo Nordisk's investigational once-weekly cagrilintide + semaglutide combination. Grade A Phase 3 RCT data, ~20-23% weight loss, and a 2026 legal status that is still investigational worldwide.
A clinical monograph on davalintide (AC2307) — Amylin Pharmaceuticals' second-generation amylin-mimetic peptide. Robust rodent fat-loss data, one unreported Phase 2 trial, and a program discontinued in 2010.
A clinical monograph on cagrilintide — the long-acting amylin analogue and amylin half of CagriSema. Genuine phase 3 human RCTs, ~22.7% combination weight loss, and an unapproved 2026 legal status.
A clinical monograph on adipotide (FTPP) — the fat-targeted proapoptotic peptide that shrinks white fat by ablating its blood supply. Dramatic preclinical fat loss, no completed human trial, and a documented kidney-toxicity signal.
Weight Loss Peptides is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Weight Loss Peptides, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.